5AM Venture Management LLC Grows Stock Holdings in Tyra Biosciences, Inc. $TYRA

5AM Venture Management LLC raised its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 9.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,029,298 shares of the company’s stock after buying an additional 90,000 shares during the quarter. Tyra Biosciences comprises about 8.5% of 5AM Venture Management LLC’s portfolio, making the stock its 3rd largest position. 5AM Venture Management LLC’s holdings in Tyra Biosciences were worth $27,060,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd bought a new position in Tyra Biosciences in the 4th quarter valued at about $51,000. Chung Wu Investment Group LLC acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $53,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Tyra Biosciences by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Tyra Biosciences by 14.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock valued at $126,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after purchasing an additional 2,766 shares in the last quarter. 84.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

TYRA has been the topic of a number of research analyst reports. Canaccord Genuity Group initiated coverage on shares of Tyra Biosciences in a research note on Monday, April 6th. They issued a “buy” rating and a $50.00 price target on the stock. JonesTrading started coverage on shares of Tyra Biosciences in a research note on Wednesday. They issued a “buy” rating and a $56.00 price target on the stock. Guggenheim started coverage on shares of Tyra Biosciences in a research report on Tuesday, April 14th. They set a “buy” rating and a $54.00 target price on the stock. Wolfe Research started coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 target price on shares of Tyra Biosciences in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Stock Performance

Shares of NASDAQ TYRA opened at $29.07 on Thursday. The company has a market capitalization of $1.73 billion, a P/E ratio of -13.33 and a beta of 0.75. Tyra Biosciences, Inc. has a 52-week low of $8.98 and a 52-week high of $40.65. The company’s 50 day moving average price is $33.04 and its 200-day moving average price is $31.20.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Analysts forecast that Tyra Biosciences, Inc. will post -2.69 earnings per share for the current year.

Insider Activity

In other news, Director Gilla Kaplan sold 14,295 shares of the business’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director owned 28,231 shares in the company, valued at approximately $1,043,700.07. The trade was a 33.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.50% of the company’s stock.

Tyra Biosciences Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.